| COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study J Avouac, E Drumez, E Hachulla, R Seror, S Georgin-Lavialle, ... The Lancet Rheumatology 3 (6), e419-e426, 2021 | 257 | 2021 |
| Adult onset Still's disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions ATJ Maria, A Le Quellec, C Jorgensen, I Touitou, S Rivière, P Guilpain Autoimmunity Reviews 13 (11), 1149-1159, 2014 | 177 | 2014 |
| Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia P Guilpain, C Le Bihan, V Foulongne, P Taourel, N Pansu, ATJ Maria, ... Annals of the rheumatic diseases 80 (1), e10-e10, 2021 | 140 | 2021 |
| Adipose-derived mesenchymal stem cells in autoimmune disorders: state of the art and perspectives for systemic sclerosis ATJ Maria, M Maumus, A Le Quellec, C Jorgensen, D Noël, P Guilpain Clinical reviews in allergy & immunology 52, 234-259, 2017 | 122 | 2017 |
| Human adipose mesenchymal stem cells as potent anti-fibrosis therapy for systemic sclerosis ATJ Maria, K Toupet, M Maumus, G Fonteneau, A Le Quellec, ... Journal of autoimmunity 70, 31-39, 2016 | 111 | 2016 |
| Sicca/Sjögren’s syndrome triggered by PD-1/PD-L1 checkpoint inhibitors. Data from the International ImmunoCancer Registry (ICIR) M Ramos-Casals, A Maria, ME Suárez-Almazor, O Lambotte, BA Fisher, ... Clin Exp Rheumatol 37 (Suppl 118), 114-22, 2019 | 92 | 2019 |
| Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors Annals of the Rheumatic Diseases 80 (4), 527-538, 2021 | 89 | 2021 |
| Antifibrotic, antioxidant, and immunomodulatory effects of mesenchymal stem cells in HOCl‐induced systemic sclerosis ATJ Maria, K Toupet, C Bony, N Pirot, MC Vozenin, B Petit, P Roger, ... Arthritis & rheumatology 68 (4), 1013-1025, 2016 | 87 | 2016 |
| Mastitis in autoimmune diseases: review of the literature, diagnostic pathway, and pathophysiological key players R Goulabchand, A Hafidi, P Van de Perre, I Millet, ATJ Maria, J Morel, ... Journal of Clinical Medicine 9 (4), 958, 2020 | 82 | 2020 |
| Zika virus infections in three travellers returning from South America and the Caribbean respectively, to Montpellier, France, December 2015 to January 2016 AT Maria, M Maquart, A Makinson, O Flusin, M Segondy, I Leparc-Goffart, ... Eurosurveillance 21 (6), 30131, 2016 | 82 | 2016 |
| Worsening and newly diagnosed paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 immunotherapies, a descriptive study G Manson, ATJ Maria, F Poizeau, FX Danlos, M Kostine, S Brosseau, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 81 | 2019 |
| Intriguing relationships between cancer and systemic sclerosis: role of the immune system and other contributors ATJ Maria, L Partouche, R Goulabchand, S Rivière, P Rozier, C Bourgier, ... Frontiers in immunology 9, 3112, 2019 | 81 | 2019 |
| Mesenchymal stem cells in systemic sclerosis: allogenic or autologous approaches for therapeutic use? P Rozier, A Maria, R Goulabchand, C Jorgensen, P Guilpain, D Noël Frontiers in immunology 9, 2938, 2018 | 62 | 2018 |
| A Phase II prospective trial of azacitidine in steroid-dependent or refractory systemic autoimmune/inflammatory disorders and VEXAS syndrome associated with MDS and CMML A Mekinian, LP Zhao, S Chevret, K Desseaux, L Pascal, T Comont, ... Leukemia 36 (11), 2739-2742, 2022 | 52 | 2022 |
| Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective … SE Sattui, R Conway, MS Putman, AM Seet, MA Gianfrancesco, K Beins, ... The Lancet Rheumatology 3 (12), e855-e864, 2021 | 52 | 2021 |
| Comparison between idiopathic and VEXAS-relapsing polychondritis: analysis of a French case series of 95 patients MY Khitri, AF Guedon, S Georgin-Lavialle, B Terrier, D Saadoun, ... RMD open 8 (2), e002255, 2022 | 45 | 2022 |
| Mesenchymal stromal cells-derived extracellular vesicles alleviate systemic sclerosis via miR-29a-3p P Rozier, M Maumus, ATJ Maria, K Toupet, J Lai-Kee-Him, C Jorgensen, ... Journal of autoimmunity 121, 102660, 2021 | 40 | 2021 |
| The plasmatic aldosterone and C-reactive protein levels, and the severity of Covid-19: the Dyhor-19 study O Villard, D Morquin, N Molinari, I Raingeard, N Nagot, JP Cristol, B Jung, ... Journal of clinical medicine 9 (7), 2315, 2020 | 40 | 2020 |
| Fibrosis development in HOCl-induced systemic sclerosis: a multistage process hampered by mesenchymal stem cells ATJ Maria, K Toupet, M Maumus, P Rozier, MC Vozenin, A Le Quellec, ... Frontiers in immunology 9, 2571, 2018 | 35 | 2018 |
| Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database ATJ Maria, C Ladhari, P Palassin, X Quantin, C Lesage, G Taïeb, ... Annals of the Rheumatic Diseases 81 (2), e32-e32, 2022 | 29 | 2022 |
